Pharmena S.A.
PHR.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.32 | -0.00 | 0.60 | 0.55 |
| FCF Yield | -6.36% | 41.37% | 2.55% | -4.03% |
| EV / EBITDA | -12.17 | 1.60 | -549.79 | -27.35 |
| Quality | ||||
| ROIC | -13.21% | 129.11% | -15.50% | -89.89% |
| Gross Margin | 73.88% | 59.40% | 3,456.52% | 51.48% |
| Cash Conversion Ratio | 2.01 | 1.14 | -1.29 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.58% | -13.53% | -68.89% | 11.08% |
| Free Cash Flow Growth | -108.29% | 1,953.86% | 144.95% | -44.24% |
| Safety | ||||
| Net Debt / EBITDA | 0.44 | -0.62 | -66.29 | -2.35 |
| Interest Coverage | 0.00 | 65.79 | -0.70 | -15.03 |
| Efficiency | ||||
| Inventory Turnover | 0.10 | 8.98 | 1.90 | 2.13 |
| Cash Conversion Cycle | 1,412.29 | -17.38 | 4,541.31 | 4.73 |